Usage, risk, and benefit of weight-loss drugs in primary care

Journal of Obesity

Volumn 2011, Issue , 2011, Pages

  Forslund, Tomas ^a   Raaschou, Pauline ^b   Hjemdahl, Paul ^b   Krakau, Ingvar ^c   Wettermark, Björn ^d  

^a Gröndal Health Centre   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM COUNTY COUNCIL   (Sweden)

^d Drug Management and Informatics   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857029672     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2011/459263     Document Type: Article

References (27)

1. Haslam D. W., James W. P. T., Obesity. Lancet 2005 366 9492 1197 1209 2-s2.0-25844457693 10.1016/S0140-6736(05)67483-1 (Pubitemid 41393598)
2. World Health Organization (WHO). Obesity and overweight. Fact sheet No 311, 2010, http://www.who.int/mediacentre/factsheets/fs311/en/index.html
3. Neovius M., Janson A., Rössner S., Prevalence of obesity in Sweden. Obesity Reviews 2006 7 1 1 3 2-s2.0-33645098767 10.1111/j.1467-789x.2006.00190.x
4. Bray G. A., Contemporary Diagnosis and Management of Obesity and the Methabolic Syndrome 2003 3rd Newtown, Pa, USA Handbooks in Health Care
5. Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant),. EMEA, 2008, http://www.ema.europa.eu/ humandocs/PDFs/EPAR/acomplia/53715308en.pdf
6. European medicines agency recommends suspension of marketing authorisation for sibutramine. EMEA, 2010, http://www.ema.europa.eu/ema/index. jsp?curl=pages/news-and-events/news/2010/01/news-detail-000985.jsp
7. Lorcaserin hydrochloride APD-356 for obesity or overweight people with at least one co-morbidity. National Horizon Scanning Centre, University of Birmingham, 2008, http://www.haps.bham.ac.uk/publichealth/horizon/outputs/ documents/2008/may-august/Lorcaserin-hydrochloride-APD-356-.pdfk
8. Astrup A., Madsbad S., Breum L., Jensen T. J., Kroustrup J. P., Larsen T. M., Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet 2008 372 9653 1906 1913 2-s2.0-56649112848 10.1016/S0140-6736(08) 61525-1
9. Wettermark B., Persson M. E., Wilking N., Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Services Research 2010 10 128
10. Wettermark B., Raaschou P., Forslund T., Hjemdahl P., Fortsatta frågetecken kring bantningsmedlet rimonabant. Läkartidningen 2007 104 51-52 3879 3881 2-s2.0-38149063773
11. Summary of product characteristics, Acomplia. EMEA, 2010, http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000666/WC500021287.pdf
12. Rucker D., Padwal R., Li S. K., Curioni C., Lau D. C. W., Long term pharmacotherapy for obesity and overweight: updated meta-analysis. The British Medical Journal 2007 335 7631 1194 1199 2-s2.0-37249083878 10.1136/bmj.39385. 413113.25 (Pubitemid 350273303)
13. Summary of product characteristics, Xenical. eMC, 2011, http://www.medicines.org.uk/emc/document.aspx?documentid=1746
14. Summary of product characteristics, Reductil. eMC, 2010, http://www.medicines.org.uk/emc/medicine/14056/SPC
15. Engfeldt P., Popa C., Bergensand P., Kvalitetsarbete kring läkemedelsförskrivning i primärvården. Nytt databasprogram underlättar uppföljning av läkemedelsbehandling. Läkartidningen 2001 98 50 5767 5771 2-s2.0-0035852381 (Pubitemid 33742055)
16. Norman C., Zarrinkoub R., Hasselström J., Godman B., Granath F., Wettermark B., Potential savings without compromising the quality of care. International Journal of Clinical Practice 2009 63 9 1320 1326 2-s2.0-68949197590 10.1111/j.1742-1241.2009.02129.x
17. Wettermark B., Hammar N., Fored C. M., The new swedish prescribed drug register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology and Drug Safety 2007 16 7 726 735 2-s2.0-34547504685 10.1002/pds.1294 (Pubitemid 47180362)
18. Caetano P. A., Lam J. M. C., Morgan S. G., Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clinical Therapeutics 2006 28 9 1411 1424 2-s2.0-33750047541 10.1016/j.clinthera.2006.09.021 (Pubitemid 44585292)
19. Mason A., New medicines in primary care: a review of influences on general practitioner prescribing. Journal of Clinical Pharmacy and Therapeutics 2008 33 1 1 10 2-s2.0-38349011290 10.1111/j.1365-2710.2008.00875.x
20. Law M. R., Majumdar S. R., Soumerai S. B., Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. The British Medical Journal 2008 337 a1055 2-s2.0-51649101870 10.1136/bmj.a1055
21. Gilbody S., Wilson P., Watt I., Benefits and harms of direct to consumer advertising: a systematic review. Quality and Safety in Health Care 2005 14 4 246 250 2-s2.0-23644455625 10.1136/qshc.2004.012781 (Pubitemid 41133177)
22. Padwal R., Kezouh A., Levine M., Etminan M., Long-term persistence with orlistat and sibutramine in a population-based cohort. The International Journal of Obesity 2007 31 10 1567 1570 2-s2.0-34748899434 10.1038/sj.ijo.0803631 (Pubitemid 47482652)
23. Johansson K., Neovius K., Desantis S. M., Rössner S., Neovius M., Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obesity Reviews 2009 10 5 564 575 2-s2.0-69449091278 10.1111/j.1467-789X.2009.00581.x
24. Després J. P., Golay A., Sjöström L., Rimonabant in Obesity-Lipids Study Group, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England Journal of Medicine 2005 353 20 2121 2134 (Pubitemid 41653104)
25. Van Gaal L. F., Rissanen A. M., Scheen A. J., Ziegler O., Rössner S., Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study. Lancet 2005 365 9468 1389 1397 2-s2.0-17144382751 10.1016/S0140-6736(05)66374-X (Pubitemid 40523733)
26. Scheen A. J., Finer N., Hollander P., Jensen M. D., Van Gaal L. F., Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006 368 9548 1660 1672 (Pubitemid 46048528)
27. Pi-Sunyer F. X., Aronne L. J., Heshmati H. M., Devin J., Rosenstock J., Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. The Journal of the American Medical Association 2006 368 9548 1660 1672